Get started
Author

Robert Zielinski

Observed names: R R Zielinski, R Zielinski, R. Zielinski, R., Zielinski, R.R. Zielinski, Rob Zielinski, Robert R Zielinski, Robert R. Zielinski, Robert Richard Zielinski, Zielinski, Robert
Observed institutions: BC Cancer Agency, Roswell Park Comprehensive Cancer Center, The University of Sydney, Charles Sturt University, The University of Melbourne, Royal North Shore Hospital, Peter MacCallum Cancer Centre, Government of New South Wales, Chris O’Brien Lifehouse, Dubbo Hospital, Eastern Health, Western NSW Local Health District, Buffalo Medical Group, Health Biomed (China), Monash Health, Beaumont Hospital, Dearborn, Cancer Research UK Oxford Centre, Daiwa Pharmaceutical Co. (Japan), Monash University, University at Buffalo, State University of New York, Western Sydney University, McMaster University
ORCID: 0000-0002-4807-8523
Observed ORCID: 0000-0002-4807-8523
OpenAlex ID: A5021031069
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
2019 · Ian D. Davis, Andrew J. Martin, et al. · New England Journal of Medicine · 1,629
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
2025 · Maria De Santis, Joan Palou Redorta, et al. · The Lancet · 77
Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: a systematic review from 2010 to 2021
2021 · Shannen R. van der Kruk, Phyllis Butow, et al. · Supportive Care in Cancer · 77
PDF
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP
2021 · Martin R. Stockler, Andrew J. Martin, et al. · Journal of Clinical Oncology · 61
PDF
Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
2022 · Ian D. Davis, Andrew James Martin, et al. · Journal of Clinical Oncology · 54
Targeting the Apoptosis Pathway in Prostate Cancer
2013 · Robert R. Zielinski, Bernhard J. Eigl, et al. · The Cancer Journal · 54
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
2021 · Christopher J. Sweeney, Andrew J. Martin, et al. · European Urology · 50
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
2025 · John W K Chia, Eva Segelov, et al. · ˜The œLancet. Gastroenterology & hepatology · 38
Is MUGA Scan Necessary in Patients With Low-Risk Breast Cancer Before Doxorubicin-Based Adjuvant Therapy?
2001 · Michael S. Sabel, Ellis G. Levine, et al. · American Journal of Clinical Oncology · 33
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
2024 · Nizar M. Tannir, Maria Nirvana Formiga, et al. · Journal of Clinical Oncology · 29
Consensus minimum data set for lung cancer multidisciplinary teams: Results of a Delphi process
2018 · Emily Stone, Nicole Rankin, et al. · Respirology · 26
Custirsen (OGX-011): A Second-Generation Antisense Inhibitor of Clusterin in Development for the Treatment of Prostate Cancer
2012 · Robert Zielinski, Kim N Chi · Future Oncology · 25
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
2024 · Luke S McLean, Annette M Lim, et al. · The Medical Journal of Australia · 21
PDF
Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).
2024 · Ronan Andrew Mc Laughlin, Hayley Thomas, et al. · Journal of Clinical Oncology · 12
PDF
Feasibility and preliminary effectiveness of virtual reality as a patient education tool for people with cancer undergoing immunotherapy: a protocol for a randomised controlled pilot study in a regional setting
2023 · Shannen R van der Kruk, Kate M Gunn, et al. · BMJ Open · 11
PDF
Efficacy and Mechanisms of Biventricular and Left/Right Direct Cardiac Compression in Acute Heart Failure Sheep
2006 · Gabrielle L. Gallagher, Yifei Huang, et al. · Artificial Organs · 11
8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
2025 · Alison Yan Zhang, Ian D. Davis, et al. · Journal of Clinical Oncology · 10
PDF
‘The best thing since sliced bread’: Patient experiences of teleoncology in western NSW
2022 · Sid Pye, Emma Webster, et al. · Australian Journal of Rural Health · 10
PDF
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
2021 · Michele Maio, Matteo S. Carlino, et al. · European Journal of Cancer · 10
Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians
2021 · G. Chazan, F. Franchini, et al. · ESMO Open · 10
PDF
Non-adenine based purines accelerate wound healing
2006 · Shucui Jiang, Caleb C. J. Zavitz, et al. · Purinergic Signalling · 10
PDF
Implementation and evaluation of a smoking cessation checklist implemented within Australian cancer services
2022 · Alison Luk Young, Nicole M. Rankin, et al. · Asia-Pacific Journal of Clinical Oncology · 9
Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers
2025 · Matteo S. Carlino, Bo Gao, et al. · JAMA Oncology · 8
A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer
2014 · Ravinder Clayton, Jackson Wu, et al. · Canadian Urological Association Journal · 8
PDF
Rice bran arabinoxylan compound and quality of life of cancer patients (RBAC-QoL): Study protocol for a randomized pilot feasibility trial
2020 · Soo Liang Ooi, Sok Cheon Pak, et al. · Contemporary Clinical Trials Communications · 7
PDF
Works count: 67
Citation count: 2,354
H-index: 13
I10-index: 21
Year
Topic
Type